Detail
| LncRNA Name | MALAT1 |
| Synonyms | MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853, PRO1073, MALAT-1, mascRNA |
| Region | GRCh38_11:65497688-65506516 Sequence |
| Ensembl | ENSG00000251562 |
| RefSeq | NR_002819 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR, Western blot etc. |
| Sample | cell lines (SiHa and HeLa) |
| Expression Pattern | down-regulated |
| Function Description | Real-time PCR and Western blotting were used to measure the gene and protein expression, respectively, of microRNA (miRNA) miR-142-3p, long non-coding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript-1 (MALAT1), and high-mobility group AT-hook 2 (HMGA2). We found that metformin could suppress cervical cancer migration and invasion. During the process of tumor metastasis, miR-142-3p was significantly upregulated, whereas lncRNA MATAL1 and HMGA2 were suppressed by metformin. The binding site that allow the direct interaction between miR-142-3p and MALAT1 were located in the 3' untranslated region (3' UTR) of lncRNA MATAL1 and HMGA2 at base pairs (bp) 4452-5255, while that between miR-142-3p and HMGA2 was located at bp 1562-2521 of HMGA2. |
| Pubmed ID | 29704494 |
| Year | 2018 |
| Title | Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells. |
| External Links |
| Links for MALAT1 | GenBank HGNC lncrnadb Noncode |
| Links for cervical cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.